GSK acquires full rights to mRNA candidate vaccines
GSK acquires full rights to develop, manufacture and commercialise globally mRNA candidate vaccines for influenza and COVID-19, including combinations...
GSK intends to completely offload Haleon shares
LONDON, UK: GSK plc (LSE/NYSE: GSK) it intends to sell approximately 385 million ordinary shares in Haleon, equivalent to approximately 4.2% of Haleon’s issued share...
GSK completes sale of shares in Haleon
LONDON: GSK plc announced that, further to its announcement on 16 January 2024, GSK has agreed to sell 300m ordinary shares in Haleon plc at...
GSK to buy Aiolos Bio for $1.4 billion, boosting its respiratory portfolio
GSK completes acquisition of Aiolos Bio LONDON: GSK plc, a global pharmaceutical company, announced today that it has agreed to acquire Aiolos Bio, Inc., a...
GSK agrees to acquire Sierra Oncology for $1.9bn
LONDON, UK: GlaxoSmithKline plc (LSE: GSK) and Sierra Oncology Inc (Nasdaq: SRRA) have entered into an agreement under which GSK will acquire Sierra Oncology, a...
GSK announced positive headline results from five studies
LONDON, UK: GlaxoSmithKline plc announced positive headline results from five studies of the Phase 3 ASCEND programme, evaluating the efficacy and safety profile of daprodustat,...
GSK sets new environmental goals
LONDON: GSK has announced ambitious new environmental sustainability goals in both climate and nature, aiming to have a net zero impact on climate and a...
GSK sells its holding in Hindustan Unilever Limited
LONDON: On 1 April 2020 GlaxoSmithKline plc (GSK) announced the completion of its divestment of Horlicks and other Consumer Healthcare nutrition products in India to...